Xemilofiban/orbofiban: Insight into drug development

Cardiovascular Drug Reviews

Volumn 19, Issue 2, 2001, Pages 116-132

  Anders, Robert ^a   Kleiman, Jay ^a   Nicholson, Nancy ^a   Wazowicz, Betty ^a   Burns, Dan ^a  

^a PFIZER INC   (United States)

Author keywords

Angioplasty; Antiplatelet drugs; Coronary artery syndrome; Myocardial infarction; Plaque rupture; Platelet glycoprotein GP IIb IIIa antagonists; Thrombosis; Unstable angina

Indexed keywords

3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; ORBOFIBAN; SC 57101; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLEEDING; BLEEDING TIME; CLINICAL TRIAL; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LONG TERM CARE; META ANALYSIS; NONHUMAN; NORMAL HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0034900053     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2001.tb00059.x     Document Type: Review

References (39)

1. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
2. Demonstration of potent inhibition of platelet aggregation with an orally active GPIIb/IIIa receptor antagonist
3. Secondary prevention of vascular disease by prolonged antiplatelet treatment
4. In vivo models of arterial thrombosis and thrombolysis
5. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) Trial
6. Platelet activation in unstable coronary disease
7. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis
8. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis
9. Increased platelet reactivity in patients given orbofiban after acute coronary syndrome: An OPUS-TIMI 16 sub-study
10. Integrins: A family of cell surface receptors
11. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
12. Buccal mucosa bleeding of healthy dogs and of dogs in various pathologic states, including thrombocytopenia, uremia, and von Willebrand disease
13. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab, administration for complex coronary intervention
14. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment
15. Pharmacodynamic efficacy, clinical safety and outcome after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial
16. Glycoprotein IIb/IIIa integrin blockade
17. Human platelets possess an inducible and saturable receptor specific for fibrinogen
18. Orbofiban: An orally active GPIIB/IIIa platelet receptor antagonist
19. In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent
20. SC-54684A: An orally active inhibitor of platelet aggregation
21. Design and objectives of the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events (EXCITE) study
22. Orobofiban is a safe, potent antiplatelet agent without significant pharmacodynamic interaction with heparin
23. Multiple-dose orobofiban is a potent oral antiplatelet agent that demonstrates a dose-dependent response
24. 3) inhibitors
25. The platelet membrane glycoprotein IIb-IIIa complex
26. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets
27. New perspectives in cell adhesion: RGD and integrins
28. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban unstable angina patients with percutaneous coronary interventions
29. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention
30. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
31. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
32. Platelet glycoprotein IIb/III receptor blockade and low-dose heparin during percutaneous coronary revascularization
33. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with the use of glycoprotein IIb/IIIla blockade
34. Randomized placebo-controlled trial of the effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
35. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial
36. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
37. 3 blockade with percutaneous coronary intervention
38. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease